Free Trial

uniQure Q2 2024 Earnings Report

uniQure logo
$14.05 -0.16 (-1.13%)
As of 01/17/2025 04:00 PM Eastern

uniQure EPS Results

Actual EPS
-$1.16
Consensus EPS
-$1.24
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

uniQure Revenue Results

Actual Revenue
$11.13 million
Expected Revenue
$3.47 million
Beat/Miss
Beat by +$7.66 million
YoY Revenue Growth
N/A

uniQure Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

uniQure Earnings Headlines

Brokerages Set uniQure (NASDAQ:QURE) Target Price at $33.88
uniQure Announces Pricing of its Public Offering
Stop guessing when stocks will move (use this)
Ever wonder why most traders make trading so complicated? Charts everywhere… Indicators on top of indicators… Eyes glued to screens all day. Here's something wild I discovered after analyzing 10 years of market data… The best trading system might just be... a calendar. Sounds crazy… But stick with me for a minute... I noticed that the most popular stocks have specific dates when they love to move up. Not random dates. Not "sometimes" dates. But precise windows of time that repeat year after year... for an entire decade.
uniQure Announces Proposed Public Offering
See More uniQure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email.

About uniQure

uniQure (NASDAQ:QURE) N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

View uniQure Profile

More Earnings Resources from MarketBeat